Table 2.
The clinical findings in HSCT patients.
| Symptoms | |
|---|---|
| Fever | 23 (69.7%) |
| Cough | 14 (42.4%) |
| Myalgia | 18 (54.6%) |
| Headache | 19 (57.6%) |
| Anosmia | 14 (42.4%) |
| Diarrhea | 5 (15.2%) |
| Sore throat | 4 (12.1%) |
| Shortness of Breath | 10 (30.3%) |
| COVID-19 Severity | |
| Mild | 20 (60.6 %) |
| Moderate | 9 (27.3 %) |
| Severe or Critical Disease | 4 (12.1 %) |
| Hospitalization | |
| n (%) | 15 (45.5%) |
| Days, median (min-max) | 12 (1-57) days |
| Treatment for COVID-19 (n, %) | |
| Hydroxychloroquine + Favipiravir | 5 (15.6%) |
| Favipiravir | 24 (75%) |
| Azithromycin + Hydroxychloroquine | 3 (9.4%) |
| Intensive Care Unit Admission | |
| n (%) | 4 (12.1%) |
| Days (mean ± SD) | 15.2 ± 12.7 |
| Mechanical Ventilation, n (%) | 3 (9.1%) |
| Case Fatality Rate | 3/33 (9.1%) |
| Duration to Death from COVID-19 (days) (mean ± SD) | 14.6 ± 6.8 |